期刊
MOLECULAR AND CELLULAR BIOCHEMISTRY
卷 476, 期 11, 页码 4177-4189出版社
SPRINGER
DOI: 10.1007/s11010-021-04230-1
关键词
Drug repositioning; Combination therapy; Precision medicine; Companion diagnostic; Metastasis and TNBC
类别
资金
- Department of Science & Technology, Science and Engineering Research Board (DST-SERB) [EMR/2017/003312]
- Government of India
Triple-negative breast cancer is known for its aggressive metastatic behavior to the brain and bone. Drug repositioning plays a vital role in precision medicine, guiding the development of new therapies and drugs.
Despite the existing therapies and lack of receptors such as HER-2, estrogen receptor and progesterone receptor, triple-negative breast cancer is one of the most aggressive subtypes of breast cancer. TNBCs are known for their highly aggressive metastatic behavior and typically migrate to brain and bone for secondary site propagation. Many diseases share similar molecular pathology exposing new avenues in molecular signaling for engendering innovative therapies. Generation of newer therapies and novel drugs are time consuming associated with very high resources. In order to provide personalized or precision medicine, drug repositioning will contribute in a cost-effective manner. In our study, we have repurposed and used a neoteric combination of two drug molecules namely, fluvoxamine and tivozanib, to target triple-negative breast cancer growth and progression. Our combination regime significantly targets two diverse but significant pathways in TNBCs. Subsequent analysis on migratory, invasive, and angiogenic properties showed the significance of our repurposed drug combination. Molecular array data resulted in identifying the specific and key players participating in cancer progression when the drug combination was used. The innovative combination of fluvoxamine and tivozanib reiterates the use of drug repositioning for precision medicine and subsequent companion diagnostic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据